PTUPB

PTUPB is a dual inhibitor of soluble epoxide hydrolase (sEH) and COX-2 (IC₅₀s = 0.009 and 1.26 µM, respectively).¹ It is selective for sEH and COX-2 over COX-1 (IC₅₀ = >100 µM). PTUPB (10 mg/kg) increases latency to paw withdrawal in the von Frey mechanical assay in a rat model of LPS-induced inflammatory pain. It inhibits VEGF-induced angiogenesis in a Matrigel^™ plug assay in mice, as well as reduces the number of metastases in a murine Lewis lung carcinoma model, when administered at a dose of 30 mg/kg per day.² PTUPB reduces body and hepatic weights, as well as hepatic triglyceride and cholesterol levels and collagen deposition in a mouse model of high-fat diet-induced non-alcoholic fatty liver disease (NAFLD).³

WARNING This product is not for human or veterinary use.

1. Hwang, S.H., Wagner, K.M., Morisseau, C., et al. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. J. Med. Chem. 54(8), 3037-3050 (2011).

2. Zhang, G., Panigrahy, D., Hwang, S.H., et al. Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 111(30), 11127-11132 (2014).

3. Sun, C.-C., Zhang, C.-Y., Duan, J.-X., et al. PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice. Biochem. Biophys. Res. Commun. 523(4), 1020-1026 (2020).